Agios Pharmaceuticals (AGIO) News Today $34.30 -0.20 (-0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.31 +0.01 (+0.03%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PTJune 15 at 7:10 PM | msn.comHC Wainwright Has Negative Outlook for AGIO FY2026 EarningsJune 13 at 2:37 AM | americanbankingnews.comFY2026 Earnings Forecast for AGIO Issued By HC WainwrightAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for Agios Pharmaceuticals in a research note issued to investors on Monday, June 9th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical compaJune 12 at 8:50 AM | marketbeat.comAgios Pharmaceuticals: A More Compelling ValuationJune 12 at 3:18 AM | seekingalpha.comCantor Fitzgerald Predicts AGIO FY2026 EarningsJune 11, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for AGIO FY2026 EarningsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the biopharmaceutiJune 10, 2025 | marketbeat.comAgios stock rises on European distribution dealJune 10, 2025 | au.investing.comAvanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood DisordersJune 9, 2025 | businesswire.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Holdings Lowered by Millennium Management LLCMillennium Management LLC lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 71.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 22,196 shares of the biopharmaceutical company's stock after selling 55,734 shares duJune 7, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,606 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 122,835 shares of the biopharmaceutical company's sJune 5, 2025 | marketbeat.comVertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?June 4, 2025 | msn.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by BrokeragesAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have issuedJune 4, 2025 | marketbeat.comTwo Sigma Advisers LP Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Two Sigma Advisers LP acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 22,200 shares of the biopharmaceutical compaJune 3, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Ameriprise Financial Inc. trimmed its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 46.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,262 shares of the biopharmaceutical compJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Makes New $3.59 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Two Sigma Investments LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 109,373 shares of the biopharmaceutical company's stock, vaMay 31, 2025 | marketbeat.comAgios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025May 28, 2025 | globenewswire.com162,415 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Bought by Squarepoint Ops LLCSquarepoint Ops LLC bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 162,415 shares of the biopharmaceutical company's stock, valued atMay 27, 2025 | marketbeat.comWhat is Zacks Research's Estimate for AGIO Q2 Earnings?Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Zacks Research raised their Q2 2025 EPS estimates for Agios Pharmaceuticals in a report released on Thursday, May 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of ($1.77) peMay 27, 2025 | marketbeat.comBank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Bank of America Corp DE lifted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 404,902 shares of the biopharmaceutical coMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Has $35.15 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Frazier Life Sciences Management L.P. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,069,754 sharMay 23, 2025 | marketbeat.comTwinbeech Capital LP Purchases Shares of 141,073 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Twinbeech Capital LP purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 141,073 shares of the biopharMay 23, 2025 | marketbeat.comAgios Pharmaceuticals at RBC Capital: Strategic Moves in Rare DiseasesMay 22, 2025 | investing.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,313 shares of the biopharmaceuticalMay 22, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Tema Etfs LLC bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 25,735 shares of the biopharmaceutical company's stock, valued at approximately $846,000. AMay 20, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Polar Capital Holdings PlcPolar Capital Holdings Plc decreased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 37.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 627,036 shares of the biopharmaceutical comMay 18, 2025 | marketbeat.comParadigm Biocapital Advisors LP Makes New $9.08 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Paradigm Biocapital Advisors LP bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 276,439 shares of the biopharmaceutical compMay 16, 2025 | marketbeat.comPatient Square Capital LP Invests $4 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Patient Square Capital LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 121,732 shares of the biopharmaceutical company'May 16, 2025 | marketbeat.comDeutsche Bank AG Boosts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Deutsche Bank AG grew its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 39.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 935,252 shares of the biopharmaceutical company's stock aMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Invests $877,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Orbimed Advisors LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 26,700 shares of the biopharmaceutical compaMay 15, 2025 | marketbeat.comMoore Capital Management LP Sells 40,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Moore Capital Management LP lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,000 shares of the biopharmaceutical company'May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Boosts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Hudson Bay Capital Management LP boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 83.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,000 shares of the biMay 15, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 15,929 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)D. E. Shaw & Co. Inc. lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 516,475 shares of the biopharmaceuticMay 15, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stake Lessened by Algert Global LLCAlgert Global LLC lowered its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 67.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,240 shares of the biopharmaceutical compMay 15, 2025 | marketbeat.comAgios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA CongressMay 14, 2025 | globenewswire.comJefferies Financial Group Inc. Invests $49.29 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Jefferies Financial Group Inc. acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,500,000 shares of the biopharmaceutical company's stock, valuedMay 13, 2025 | marketbeat.comGranahan Investment Management LLC Sells 35,098 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Granahan Investment Management LLC lessened its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 23.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 115,687 shares of the biopharmaceutical company's stockMay 13, 2025 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)May 12, 2025 | theglobeandmail.comCrestline Management LP Acquires New Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Crestline Management LP bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,105 shares of the biopharmaceutical companMay 12, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and five have issued a buy ratingMay 12, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Balyasny Asset Management L.P. acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 248,038 shares of the biopharmaceutical company's stock, valued at appMay 12, 2025 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.comStockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday.May 12, 2025 | marketbeat.comFarallon Capital Management LLC Boosts Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Farallon Capital Management LLC grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 0.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,674,466 shares of the biopharmaceutical company's stockMay 11, 2025 | marketbeat.comJane Street Group LLC Grows Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Jane Street Group LLC lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 58.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,027 shares of the biopMay 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Reduces Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)The Manufacturers Life Insurance Company reduced its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,094 shares of the biopharMay 11, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) StockRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on April 17th. The trade occurrMay 10, 2025 | marketbeat.comAgios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For ShareholdersMay 9, 2025 | finance.yahoo.comAgios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025May 9, 2025 | globenewswire.comBrevan Howard Capital Management LP Has $1.56 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Brevan Howard Capital Management LP boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 341.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,326 shares of the biopharmaceuticalMay 9, 2025 | marketbeat.comAxa S.A. Sells 63,373 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Axa S.A. lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 26.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 175,377 shares of the biopharmaceutical company's stock after selling 63,373 shares during the period.May 9, 2025 | marketbeat.comTudor Investment Corp ET AL Makes New $938,000 Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Tudor Investment Corp ET AL purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,553 shares of theMay 9, 2025 | marketbeat.com Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Media Mentions By Week AGIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.320.89▲Average Medical News Sentiment AGIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼156▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News BridgeBio Pharma News Elanco Animal Health News Verona Pharma News Legend Biotech News TG Therapeutics News Grifols News Lantheus News Telix Pharmaceuticals Limited American Depositary Shares News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
